Doxycycline as postexposure prophylaxis (doxyPEP) is being recommended by several local and state health departments to men who have sex with men (MSM) and transgender women who have had 1 or more sexually transmitted infection (STI) in the past year, according to a JAMA Insights article.
“The Centers for Disease Control and Prevention currently suggests that clinicians engage in shared decision-making with patients who may benefit from doxyPEP,” the authors write. “Formal guidelines are being developed. Uncertainties remain about the efficacy of doxyPEP in some populations, particularly cisgender women. Although indiscriminate use of antibiotics should be avoided, offering doxyPEP to MSM and transgender women at increased risk for bacterial STIs should be considered because of the growing bacterial STI epidemic and the efficacy of doxyPEP.”